Loading...
XSWX
NWRN
Market cap142mUSD
Apr 04, Last price  
6.15CHF
1D
-5.96%
1Q
-30.19%
Jan 2017
-69.48%
IPO
-88.37%
Name

Newron Pharmaceuticals SpA

Chart & Performance

D1W1MN
P/E
—
P/S
14.36
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
17.61%
Revenues
9m
+48.62%
01,191,0004,024,0003,933,0002,542,000806,000280,0008,924,0003,539,0001,557,0002,380,0006,726,00013,428,0004,025,0007,038,0005,258,0005,762,0006,094,0009,057,000
Net income
-16m
L-7.25%
-14,919,000-16,401,000-11,089,000-16,364,000-23,481,000-20,545,000-6,445,000-2,375,000-7,098,000-10,095,000-22,816,000-15,237,000-5,282,000-15,035,000-20,207,000-20,998,000-14,901,000-17,493,000-16,224,000
CFO
-10m
L-8.58%
-14,329,000-9,630,000-13,866,000-19,932,000-23,056,000-19,127,000-4,942,0005,825,000-10,686,000-9,998,000-12,862,000-19,583,000-8,404,000-15,954,000-21,976,000-15,588,000-11,445,000-11,092,000-10,140,000
Earnings
Apr 17, 2025

Profile

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
URL
https://www.newron.com/
IPO date
Dec 12, 2006
Employees
23
Domiciled in
IT
Incorporated in
IT

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
9,057
48.62%
6,094
5.76%
Cost of revenue
17,214
19,280
Unusual Expense (Income)
NOPBT
(8,157)
(13,186)
NOPBT Margin
Operating Taxes
24
21
Tax Rate
NOPAT
(8,181)
(13,207)
Net income
(16,224)
-7.25%
(17,493)
17.39%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
22,452
172
Long-term debt
26,348
45,662
Deferred revenue
Other long-term liabilities
885
(45,165)
Net debt
36,201
23,060
Cash flow
Cash from operating activities
(10,140)
(11,092)
CAPEX
(11)
(18)
Cash from investing activities
3,246
(317)
Cash from financing activities
(192)
(186)
FCF
(7,788)
(12,678)
Balance
Cash
12,599
22,774
Long term investments
Excess cash
12,146
22,469
Stockholders' equity
(5,746)
(14,030)
Invested Capital
25,138
46,356
ROIC
ROCE
EV
Common stock shares outstanding
17,845
17,845
Price
4.95
219.35%
1.55
-4.32%
Market cap
88,333
219.35%
27,660
-4.32%
EV
136,615
50,720
EBITDA
(7,956)
(12,984)
EV/EBITDA
Interest
4,168
3,947
Interest/NOPBT